Event Categorie: Recorded

Obtaining a CPT code, either a new code or the use of an existing code, is essential for many new […]

Speaker: Ian Duncan, Santa Barbara Actuaries

https://www.youtube.com/watch?v=4U8MsI3aG0Y

Tuesday, November 16, 1:00 to 2:00 PM PT

You have developed a great new device, founded a winning healthcare startup, obtained FDA certification… but have you thought about how you will be paid for the startup/device/intervention? Don’t ignore reimbursement until it’s too late. Now is the time to start honing your economic value proposition to payers. Join us to hear from Ian Duncan of Santa Barbara Actuaries. Ian will tell us about all the key points that healthcare companies need to take into consideration when planning their reimbursement and payer strategies.

Topics to be covered:

• Does your solution address a condition or aspect of healthcare that is sufficiently costly for a payer/employer to devote its limited time and resources to? (Yes, there are some rule-of-thumb thresholds).
• What do payers care about? (answer: PMPM; but can your solution be administered?).
• What is ROI and do you need ROI evidence to support your economic case?
• How much evidence is enough evidence? Do you need peer-reviewed outcomes (probably not, though it’s nice to have).
• Calculating ROI: With and without sufficient real-world data.
• What about other aspects of the value equation (absenteeism/productivity)?
• What is the fastest and easiest way to get the evidence needed to sell?
• An interactive economic model can be a great sales tool. (All payers think their population is different to all the others).
• Have you thought about who needs your intervention from an ROI/value creation standpoint?
• Have you thought about how to optimize, not maximize, your program’s engagement?

Speakers: Shefali Shah & Louis Jacques, ADVI

https://www.youtube.com/watch?v=77bk2By7kw4

Thursday, May 27, 1:00 to 2:00 PM PST

Ever-increasing costs have kept the topic of healthcare coverage, reimbursement, and pricing in the spotlight. While innovators must be sensitive to the short-term goals of their investors, those “quick wins” in the development or regulatory phases may stymie the efficient attainment of long-term goals for favorable coverage and payment by public and commercial health insurers.  Value has become a buzzword, but what does it mean? And what does it mean to different audiences? While some feel the assessment of value is opaque and challenging, health insurers (buyers) believe that the message is clear enough but largely ignored because it doesn’t match what developers (sellers) want to hear.

Speakers: Michael Cohen, Brown Rudnick

https://www.youtube.com/watch?v=d-q2kthXNvU

Tuesday, February 9, 1:00 to 2:00 PM PST

Most emerging companies with rapid growth plans will seek venture financing.  Whether you sell SAFE, convertible notes, or preferred stock, venture investors expect that your financing will feature standard rights and use accepted documentation, but that isn’t the end of the story. Decisions about valuation, founders’ rights, and control over decision making can have long-lasting impacts on the company, and the interests of the investors will quickly deviate from those of the original stockholders. It is important to understand the financing process, where there is room to negotiate, and which investor rights are non-negotiable. This talk will walk through the process of a typical venture investment, starting at the term sheet stage and moving through the definitive documents.  We will focus on real-life examples and the consequences of certain decisions in the lead-up to closing.